Abstract
A 65-year-old male experiencing the recurrence of a solitary sigmoid cancer liver tumor was treated with bevacizumab (Bev)/XELOX chemotherapy, because he had refused surgical resection. After 5 courses, CT findings showed a partial response( 80% size-reduction)of the recurrent liver tumor. There was no recurrence in any other organ. He then requested hepatectomy, so we performed it, and there were no complications. The histological diagnosis was metastatic liver tumor, the estimation of the histological change by chemotherapy was Grade 2, and no abnormalities were found in the background of the liver. Bev/XELOX was relatively safe and successful for pre-operative patients with liver tumor recurrence.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Capecitabine
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Fluorouracil / therapeutic use
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary
-
Liver Neoplasms / surgery
-
Male
-
Neoadjuvant Therapy*
-
Oxaloacetates
-
Recurrence
-
Sigmoid Neoplasms / drug therapy*
-
Sigmoid Neoplasms / pathology
-
Sigmoid Neoplasms / surgery
-
Tomography, X-Ray Computed
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Oxaloacetates
-
Deoxycytidine
-
Bevacizumab
-
Capecitabine
-
Fluorouracil